Vandetanib

From Anvita Health Wiki

Contents 1 Indications 2 Dosage 3 Dosage-adjustment-in-renal-failure 4 Pharmacokinetics 5 Monitor 6 Adverse-effects 7 Drug-interactions 8 Mechanism-of-action 9 Notes 10 More General Terms 11 References

Indications

• symptomatic or progressive medullary thyroid cancer in patients with unresectable, locally advanced, or metastatic disease

Dosage

• 300 mg PO QD

Dosage-adjustment-in-renal-failure

• start 200 mg PO QD if creatinine clearance < 50 ml/min

Pharmacokinetics

• 1/2 life of 19 days

Monitor

• electrocardiogram
• serum potassium
• serum calcium
• serum magnesium
• serum TSH
• obtained at baseline, at 2-4 weeks & 8-12 weeks after starting treatment & subsequently every 3 months

Adverse-effects

• QT prolongation ( boxed warning)

• torsades de pointes

• sudden death

Drug-interactions

• conconcurrent use of strong CYP3A4 inhibitors may diminish levels of vandetanib; however no clinically significant interaction was found with vandetanib & itraconazole
• avoid concurrent use of other agents that may cause QT prolongation

Mechanism-of-action

• kinase inhibitor

Notes

• only prescribers & pharmacies certified through the Vandetanib Risk Evaluation Mitigation Strategy Program, a restricted distribution program, are able to prescribe & dispense vandetanib

More General Terms

• antineoplastic agent (chemotherapeutic agent)

References

1. FDA: Vandetanib [1]
2. Caprelsa (vandetanib) Tablets [2]

vandetanib (Caprelsa)